IRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped
July 10 2018 - 8:00AM
IRIDEX Corporation (Nasdaq:IRIX) today announced that in the second
quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™
Laser System, which utilizes the Company’s proprietary MicroPulse®
technology for the treatment of glaucoma. Dr. Ryo Taniguchi, of the
Taniguchi Eye Clinic in Japan, Kyoshu Saga Prefecture, was the
recipient of the 1,000th system. “MicroPulse Laser therapy is a new
and very promising technology in Japan, providing an effective and
non-incisional treatment for glaucoma patients with a range of
stages of the disease. The earlier clinical research performed in
US, Europe and Asia showed that MicroPulse is safe and effective in
IOP reduction and medication use decrease, and my clinical findings
confirm the previous studies’ results. As one of the first
sites in Japan to use the Cyclo G6 for glaucoma treatment, we have
seen significant benefits. Even patients with previous intraocular
surgeries experienced positive results,” said Makoto Aihara MD,
PhD, Professor and Chair, University of Tokyo. The Cyclo G6 system
is supported by a growing body of clinical evidence and extensive
validation in the field for the treatment of glaucoma. Physicians
worldwide have adopted the Cyclo G6 because it is safe, minimally
invasive, non-incisional, repeatable and durable. Moreover, the
Cyclo G6 provides physicians and the healthcare system a
cost-effective solution for the treatment of glaucoma across the
full continuum of care – from early to late stage glaucoma. More
than 80,000 patients worldwide have been treated with the Cyclo G6
system. “In my opinion, MicroPulse Laser therapy shifts the
paradigm of glaucoma treatments in Japan. It provides a new choice
for a safe, effective, and non-incisional treatment on various
glaucoma patients with mild, moderate, and late stage disease. The
MicroPulse procedure can be performed on a wide variety of patients
not responding to medications or not qualified for incisional
surgeries. Recent industry meetings and clinical presentations of
leading physicians using the MicroPulse procedure in the United
States, Europe and Asia have demonstrated and proven that fact. My
initial clinical experience with it confirms these findings,”
commented Dr. Ryo Taniguchi. “We are delighted to achieve this
exciting milestone in the commercialization of our Cyclo G6 laser
system, as it not only demonstrates the traction the platform is
gaining worldwide, but highlights the progress we have made in
transforming our business to delivering a compelling and proven
treatment alternative for patients suffering from glaucoma,” said
William Moore, Chief Executive Officer of IRIDEX.
About IRIDEX IRIDEX is a worldwide leader in
developing innovative and versatile laser-based medical systems,
delivery devices and consumable instrumentation for the
ophthalmology market. The Company’s proprietary MicroPulse
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the
treatment of glaucoma, diabetic macular edema (DME) and other
retinal diseases. IRIDEX products are sold in the United
States and Germany through a direct sales force and in more than
100 countries through a network of independent distributors. For
more information, visit iridex.com.
Safe Harbor
StatementThis announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Act of 1934,
as amended, including those statements concerning future sales of
Company products and industry trends. These statements are not
guarantees of future performance and actual results may differ
materially from those described in these forward-looking statements
as a result of a number of factors, including the Company’s ability
to execute on its strategic goals, market adoption of its products
and industry developments. Please see a detailed description of
these and other risks contained in our Annual Report on Form 10-K
for the fiscal year ended December 30, 2017, and Quarterly Reports
on Form 10-Q for subsequent fiscal quarters, each of which was
filed with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date
and will not be updated.
Media Contact:Jamie Hall
Pascale Communications,
LLC.724.417.0167jamie@pascalecommunications.com
Investor
Relations Contact Lynn Pieper Lewis or Leigh
Salvo 415.937.5404 investors@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Apr 2023 to Apr 2024